Hello, everyone, and how are you today? We are doing just fine, thank you, courtesy of a warm and shiny sun enveloping the Pharmalot campus. The short people have left for their destinations — the local schoolhouse and gainful employment, respectively — and the official mascots have settled in for another long round of comfortable snoozing. All of which is to say we can focus on the task ahead, which is foraging for interesting items. On that note, here are some tidbits to get you started. Hope you have a smashing and productive day …

Bristol-Myers Squibb (BMY) disclosed that a combination of two of its cancer drugs — Opdivo and Yervoy — being tested as maintenance therapy did not meet the main goal of extending the lives of extensive-stage small cell lung cancer patients in a late-stage trial, Reuters writes. Earlier this year, the FDA extended the date by which it was expected to make an approval decision on an Opdivo-Yervoy combination to treat a different form of lung cancer, in order to review new data the company had submitted.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy